<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DARAPRIM- pyrimethamineÂ tabletÂ </strong><br>Amedra Pharmaceuticals LLC<br></p></div>
<h1>DARAPRIM<span class="Sup">Â®</span><br>(pyrimethamine)<br>25-mg Scored Tablets<br>Rx Only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB1"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">PRESCRIBING INFORMATION</span></h1>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_a3ac5e9a-eff6-414d-aa6e-83b695900093"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">DARAPRIM (pyrimethamine) is an antiparasitic compound available
                            in tablet form for oral administration. Each scored tablet contains
                            25Â mg pyrimethamine and the inactive ingredients corn and
                            potato starch, lactose, and magnesium stearate. </p>
<p>Pyrimethamine, known chemically as
                            5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine, has the following
                            structural formula:</p>
<div class="Figure"><img alt="pyrimethamine chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3e4d5027-7939-480f-ae19-82e764d9fa97&amp;name=daraprim-01.jpg"></div>
<p>C<span class="Sub">12</span>H<span class="Sub">13</span>ClN<span class="Sub">4</span><br>Mol. Wt. 248.71</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_fa1bfc4b-cd9b-4837-8d98-7a76040fb40f"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Pyrimethamine is well absorbed with peak levels occurring between
                            2 to 6Â hours following administration. It is eliminated slowly
                            and has a plasma half-life of approximately 96Â hours.
                            Pyrimethamine is 87% bound to human plasma proteins.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1c92c2a7-6b4b-432c-96bc-59f003999b54"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Microbiology:</span>  Pyrimethamine is a folic acid antagonist and the
                                    rationale for its therapeutic action is based on the
                                    differential requirement between host and parasite for nucleic
                                    acid precursors involved in growth. This activity is highly
                                    selective against plasmodia and <span class="Italics">Toxoplasma gondii. </span></p>
<p>Pyrimethamine possesses blood schizonticidal and some
                                    tissue schizonticidal activity against <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> parasites of
                                    humans. However, the 4-amino-quinoline compounds are more
                                    effective against the erythrocytic schizonts. It does not
                                    destroy gametocytes, but arrests sporogony in the mosquito. </p>
<p>The action of pyrimethamine against <span class="Italics">Toxoplasma gondii</span> is greatly
                                    enhanced when used in conjunction with sulfonamides. This was
                                    demonstrated by Eyles and Coleman<span class="Sup">1</span> in the treatment
                                    of experimental <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> in the mouse. Jacobs et
                                    al<span class="Sup">2</span> demonstrated that combination of the
                                    2Â drugs effectively prevented the development of severe
                                    <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> in most rabbits following the inoculation of the
                                    anterior chamber of the eye with toxoplasma. </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_7146ccff-1771-4f85-862b-4d994d0154f5"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f8f6b061-1748-4236-89f5-62055d3a81b6"></a><a name="section-4.1"></a><p></p>
<p class="First"><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">Toxoplasmosis</span>: </span>DARAPRIM is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>
                                    when used conjointly with a sulfonamide, since synergism exists
                                    with this combination.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_79cce3df-ac14-40ba-b773-0f2f4dd3ad7c"></a><a name="section-4.2"></a><p></p>
<p class="First"><span class="Bold">Treatment of Acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>: </span>DARAPRIM is also indicated for the treatment of acute
                                    <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. It should not be used alone to treat acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.
                                    Fast-acting schizonticides such as chloroquine or quinine are
                                    indicated and preferable for the treatment of acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.
                                    However, conjoint use of DARAPRIM with a sulfonamide (e.g.,
                                    sulfadoxine) will initiate transmission control and suppression
                                    of susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of plasmodia.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9c55c767-11a5-4e34-9223-6a97753120cf"></a><a name="section-4.3"></a><p></p>
<p class="First"><span class="Bold">Chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>: </span>DARAPRIM is indicated for the chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>
                                    due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of plasmodia. However, resistance to
                                    pyrimethamine is prevalent worldwide. It is not suitable as a
                                    <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> agent for travelers to most areas.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_cb11972d-a539-4842-8e15-c96d8642a32d"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">Use of DARAPRIM is contraindicated in patients with known
                            <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to pyrimethamine or to any component of the
                            formulation. Use of the drug is also contraindicated in patients with
                            documented <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> due to <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_4fecbc43-eb79-4102-91c4-cc3b2d751652"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">The dosage of pyrimethamine required for the treatment of
                            <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> is 10 to 20Â times the recommended antimalaria
                            dosage and approaches the toxic level. If signs of <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>
                            develop (see <a href="#LINK_db86fdca-6189-4ea1-b936-c2cd64fe8e2b">ADVERSE
                                    REACTIONS</a>), reduce the dosage or discontinue the drug according to the
                            response of the patient. Folinic acid (leucovorin) should be
                            administered in a dosage of 5 to 15Â mg daily (orally, IV, or
                            IM) until normal hematopoiesis is restored. </p>
<p>Data in 2 humans indicate that pyrimethamine may be carcinogenic;
                            a 51-year-old female who developed <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic granulocytic leukemia</span> after
                            taking pyrimethamine for 2Â years for <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span><span class="Sup">3</span>
                            and a 56-year-old patient who developed reticulum cell <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> after
                            14Â months of pyrimethamine for <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>.<span class="Sup">4</span></p>
<p>Pyrimethamine has been reported to produce a significant increase
                            in the number of lung tumors in mice when given intraperitoneally at
                            doses of 25Â mg/kg.<span class="Sup">5</span></p>
<p>DARAPRIM should be kept out of the reach of infants and children
                            as they are extremely susceptible to adverse effects from an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
                            <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> in pediatric patients have been reported after accidental
                            ingestion. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_0fdea2de-db7d-4492-8a7f-8760dbd257ab"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_bae4a18b-c287-427c-b65d-ce307c0a3e87"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">General: </span>The recommended dosage for chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>
                                    should not be exceeded. A small â€œstartingâ€?
                                    dose for <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> is recommended in patients with
                                    <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span> to avoid the potential nervous system
                                    toxicity of pyrimethamine. DARAPRIM should be used with caution
                                    in patients with impaired renal or hepatic function or in
                                    patients with possible <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>, such as individuals
                                    with <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndrome</span>, <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>, or pregnancy, and those
                                    receiving therapy, such as phenytoin, affecting folate levels
                                        (seeÂ <a href="#LINK_cdcdcf89-7c83-4eec-8b1c-a99ee17b39ea">Pregnancy</a>Â subsection).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_26caeb9e-6f04-4aa7-a9ff-ef3bcdfd3250"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients: </span>Patients should be warned that at the first appearance of
                                    a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> they should stop use of DARAPRIM and seek medical
                                    attention immediately. Patients should also be warned that the
                                    appearance of <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, or <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span> may be
                                    early indications of serious disorders which require treatment
                                    with DARAPRIM to be stopped and medical treatment to be sought. </p>
<p>Women of childbearing potential who are taking DARAPRIM
                                    should be warned against becoming pregnant. Patients should be
                                    warned to keep DARAPRIM out of the reach of children. Patients
                                    should be advised not to exceed recommended doses. Patients
                                    should be warned that if <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occur, they may
                                    be minimized by taking the drug with meals.</p>
<p>Concurrent administration of folinic acid is strongly
                                    recommended when used for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> in all
                                    patients.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_6ae5bc25-f722-4a55-bc09-400c16365e55"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Laboratory Tests: </span>In patients receiving high dosage, as for the treatment
                                    of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>, semiweekly blood counts, including platelet
                                    counts, should be performed.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_d5020a23-7719-4428-b12a-0a25fcf7a63e"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions: </span>Pyrimethamine may be used with sulfonamides, quinine and
                                    other antimalarials, and with other antibiotics. However, the
                                    concomitant use of other antifolic drugs or agents associated
                                    with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> including sulfonamides or
                                    trimethoprim-sulfamethoxazole combinations, proguanil,
                                    zidovudine, or cytostatic agents (e.g., methotrexate), while the
                                    patient is receiving pyrimethamine, may increase the risk of
                                    bone marrow suppression. If signs of <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span> develop,
                                    pyrimethamine should be discontinued. Folinic acid (leucovorin)
                                    should be administered until normal hematopoiesis is restored
                                    (see <a href="#LINK_4fecbc43-eb79-4102-91c4-cc3b2d751652">WARNINGS</a>). Mild hepatotoxicity has been reported in some
                                    patients when lorazepam and pyrimethamine were administered
                                    concomitantly.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_f32eecbb-82e2-4ad0-a01c-22a4e0c4a051"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of
                                    Fertility: </span>SeeÂ <a href="#LINK_4fecbc43-eb79-4102-91c4-cc3b2d751652">WARNINGS</a> section for information on carcinogenesis.</p>
<p><span class="Italics"><span class="Bold">Mutagenesis:</span></span> Pyrimethamine has been shown to be nonmutagenic in
                                    the following <span class="Italics">in vitro</span>
                                    assays: the Ames point mutation assay, the Rec assay, and the
                                        <span class="Italics">E. coli</span> WP2 assay. It
                                    was positive in the L5178Y/TK +/- mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay in the
                                    absence of exogenous metabolic activation.<span class="Sup">6</span> Human
                                    blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> cultured <span class="Italics">in
                                    vitro</span> had structural chromosome aberrations induced by
                                    pyrimethamine. </p>
<p><span class="Italics">In vivo,</span>
                                    chromosomes analyzed from the bone marrow of rats dosed with
                                    pyrimethamine showed an increased number of structural and
                                    numerical aberrations.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_cdcdcf89-7c83-4eec-8b1c-a99ee17b39ea"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Pregnancy: </span><span class="Italics"><span class="Bold">Teratogenic Effects:</span></span> Pregnancy Category C. Pyrimethamine has been shown to
                                    be teratogenic in rats when given in oral doses 7Â times
                                    the human dose for chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> or
                                    2.5Â times the human dose for treatment of
                                    <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>. At these doses in rats, there was a significant
                                    increase in abnormalities such as <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, brachygnathia,
                                    oligodactyly, and <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>. Pyrimethamine has also been
                                    shown to produce terata such as <span class="product-label-link" type="condition" conceptid="4062639" conceptname="Meningocele">meningocele</span> in hamsters and
                                    <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in miniature pigs when given in oral doses 170 and
                                    5Â times the human dose, respectively, for
                                    chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> or for treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>.</p>
<p>There are no adequate and well-controlled studies in
                                    pregnant women. DARAPRIM should be used during pregnancy only if
                                    the potential benefit justifies the potential risk to the fetus.</p>
<p>
                                    Concurrent administration of folinic acid is strongly
                                    recommended when used for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> during
                                    pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_b962874d-5edf-4ff8-aa55-c3cdc057d917"></a><a name="section-7.7"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers: </span>Pyrimethamine is excreted in human milk. Because of the
                                    potential for serious adverse reactions in nursing infants from
                                    pyrimethamine and from concurrent use of a sulfonamide with
                                    DARAPRIM for treatment of some patients with <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>, a
                                    decision should be made whether to discontinue nursing or to
                                    discontinue the drug, taking into account the importance of the
                                    drug to the mother (see <a href="#LINK_4fecbc43-eb79-4102-91c4-cc3b2d751652">WARNINGSÂ </a>and <a href="#LINK_cdcdcf89-7c83-4eec-8b1c-a99ee17b39ea">PRECAUTIONS: Pregnancy</a>).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_3ee722f8-7e03-4fae-8705-23fb043bcfdd"></a><a name="section-7.8"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use: </span>See <a href="#LINK_7505f740-391b-4d25-af51-c65f71688c71">DOSAGE AND ADMINISTRATION</a>Â section.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_534931e2-b8a2-4361-b16c-15d380296638"></a><a name="section-7.9"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Geriatric Use: </span>Clinical studies of DARAPRIM did not include sufficient
                                    numbers of subjects aged 65 and over to determine whether they
                                    respond differently from younger subjects. Other reported
                                    clinical experience has not identified differences in responses
                                    between the elderly and younger patients. In general, dose
                                    selection for an elderly patient should be cautious, usually
                                    starting at the low end of the dosing range, reflecting the
                                    greater frequency of decreased hepatic, renal, or cardiac
                                    function, and of concomitant disease or other drug
                                therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_db86fdca-6189-4ea1-b936-c2cd64fe8e2b"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, occasionally severe (such as
                            <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>
                            multiforme, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>), and hyperphenylalaninemia, can occur
                            particularly when pyrimethamine is administered concomitantly with a
                            sulfonamide. Consult the complete prescribing information for the
                            relevant sulfonamide for sulfonamide-associated adverse events. With
                            doses of pyrimethamine used for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>
                            and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may occur. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> may be minimized by giving the
                            medication with meals; it usually disappears promptly upon reduction of
                            dosage. Doses used in <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> may produce <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>,
                            <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, atrophic <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>,
                            <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, and disorders of cardiac rhythm. Hematologic effects,
                            however, may also occur at low doses in certain individuals (see
                                <a href="#LINK_bae4a18b-c287-427c-b65d-ce307c0a3e87">PRECAUTIONS; General</a>). </p>
<p><span class="product-label-link" type="condition" conceptid="252942" conceptname="Asthmatic pulmonary eosinophilia">Pulmonary eosinophilia</span> has been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_1cef5761-298f-49c8-953d-83524c5e8bd9"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">Following the ingestion of 300Â mg or more of
                            pyrimethamine, gastrointestinal and/or central nervous system signs may
                            be present, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. The initial symptoms are usually
                            gastrointestinal and may include <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, severe and
                            repeated <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, possibly including <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Central nervous
                            system toxicity may be manifest by initial <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, generalized and
                            prolonged <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> which may be followed by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>,
                            <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> within a few hours. Neurological
                            symptoms appear rapidly (30Â minutes to 2Â hours after
                            drug ingestion), suggesting that in gross overdosage pyrimethamine has a
                            direct toxic effect on the central nervous system. </p>
<p>The fatal dose is variable, with the smallest reported fatal
                            single dose being 375Â mg. There are, however, reports of
                            pediatric patients who have recovered after taking 375 to
                            625Â mg. </p>
<p>There is no specific antidote to acute pyrimethamine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.
                            In the event of overdosage, symptomatic and supportive measures should
                            be employed. Gastric lavage is recommended and is effective if carried
                            out very soon after drug ingestion. Parenteral diazepam may be used to
                            control <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Folinic acid should be administered within
                            2Â hours of drug ingestion to be most effective in counteracting
                            the effects on the hematopoietic system (see <a href="#LINK_4fecbc43-eb79-4102-91c4-cc3b2d751652">WARNINGS</a>). Due to the long half-life of pyrimethamine, daily
                            monitoring of peripheral blood counts is recommended for up to several
                            weeks after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> until normal hematologic values are
                        restored.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_7505f740-391b-4d25-af51-c65f71688c71"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5dcdae7b-eef8-40dc-b820-e38ba93d1d67"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">For Treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">Toxoplasmosis</span>: </span>The dosage of DARAPRIM for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>
                                    must be carefully adjusted so as to provide maximum therapeutic
                                    effect and a minimum of side effects. At the dosage required,
                                    there is a marked variation in the tolerance to the drug. Young
                                    patients may tolerate higher doses than older individuals.
                                    Concurrent administration of folinic acid is strongly
                                    recommended in all patients.</p>
<p>The adult <span class="Italics">starting</span>
                                    dose is 50 to 75Â mg of the drug daily, together with 1
                                    to 4Â g daily of a sulfonamide of the sulfapyrimidine
                                    type, e.g. sulfadoxine. This dosage is ordinarily continued for
                                    1 to 3Â weeks, depending on the response of the patient
                                    and tolerance to therapy. The dosage may then be reduced to
                                    about one half that previously given for each drug and continued
                                    for an additional 4 to 5Â weeks. </p>
<p>The pediatric dosage of DARAPRIM is 1Â mg/kg/day
                                    divided into 2Â equal daily doses; after 2 to
                                    4Â days this dose may be reduced to one half and
                                    continued for approximately 1Â month. The usual
                                    pediatric sulfonamide dosage is used in conjunction with
                                    DARAPRIM. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a6a741c2-4d58-4338-b588-0b30c7d24d50"></a><a name="section-10.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">For Treatment of Acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>: </span>DARAPRIM is NOT recommended alone in the treatment of
                                    acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. Fast-acting schizonticides, such as chloroquine
                                    or quinine, are indicated for treatment of acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.
                                    However, DARAPRIM at a dosage of 25Â mg daily for
                                    2Â days with a sulfonamide will initiate transmission
                                    control and suppression of non-<span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum malaria</span><span class="Italics">.</span> DARAPRIM is only recommended
                                    for patients infected in areas where susceptible plasmodia
                                    exist. Should circumstances arise wherein DARAPRIM must be used
                                    alone in semi-immune persons, the adult dosage for acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>
                                    is 50Â mg for 2Â days; children 4 through
                                    10Â years old may be given 25Â mg daily for
                                    2Â days. In any event, clinical cure should be followed
                                    by the once-weekly regimen described below for chemoprophylaxis.
                                    Regimens which include suppression should be extended through
                                    any characteristic periods of early recrudescence and late
                                    relapse, i.e., for at least 10Â weeks in each
                                case.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2e912a2c-76a9-432f-9208-fafeae06fa38"></a><a name="section-10.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">For Chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:</span><br>Adults and pediatric patients over 10Â years â€“ 25Â mg (1 tablet) once weekly
                                    <br>Children 4 through 10Â years â€“
                                    12.5Â mg (1/2 tablet) once weekly
                                    <br>Infants and children under 4Â years â€“
                                    6.25Â mg (1/4 tablet) once weekly. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_5189c3b6-bfb9-4a5f-9311-b89245d1670d"></a><a name="section-11"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">HOW SUPPLIED: </span><br>White, scored tablets containing 25Â mg pyrimethamine,
                            imprinted with â€œDARAPRIMâ€? and
                            â€œA3Aâ€? in bottles of 100 (NDC 52054-330-10 and NDC 52054-330-95).</p>
<p><span class="Bold">Store at 15Â° to 25Â°C
                                (59Â° to 77Â°F) in a dry place and protect from
                                light. </span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_c963388d-1589-4de4-a9b2-cfb4b048034b"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">REFERENCES</span></h1>
<p class="First">1.Â Â Â Â Â  Eyles DE,
                            Coleman N. Synergistic effect of sulfadiazine and Daraprim against
                            experimental <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> in the mouse. <span class="Italics">Antibiot Chemother</span>
                            1953;3:483-490.
                            <br>2.Â Â Â Â Â  Jacobs L,
                            Melton ML, Kaufman HE. Treatment of experimental ocular <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>.
                                <span class="Italics">Arch Ophthalmol.</span>
                            1964;71:111-118.
                            <br>3.Â Â Â Â Â  Jim RTS,
                            Elizaga FV. Development of <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic granulocytic leukemia</span> in a patient
                            treated with pyrimethamine. <span class="Italics">Hawaii Med J. </span>1977;36:173-176.
                            <br>4.Â Â Â Â Â  Sadoff L.
                            Antimalarial drugs and Burkittâ€™s <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>. <span class="Italics">Lancet.</span> 1973;2:1262-1263.
                            <br>5.Â Â Â Â Â  Bahna L.
                            Pyrimethamine. <span class="Italics">LARC Monogr Eval Carcinog
                                Risk Chem.</span> 1977;13:233-242.
                            <br>6.Â Â Â Â Â Â Clive
                            D, Johnson KO, Spector JKS, et al. Validation and characterization of
                            the L5178Y/TK +/- mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mutagen
                            assay system. <span class="Italics">Mut Res.</span> 1979;59:61-108.
                        </p>
<p>Distributed by:
                            <br>Amedra Pharmaceuticals LLC
                            <br>Horsham, PA 19044
                            </p>
<p>LB# 801-03 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Rev. 10-2014
                           </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_21963111-da2a-4ced-bef4-498552957406"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL â€“ NDC 52054-330-95</span></p>
<p><img alt="Daraprim Tablets 25 mg - 100 Tablets - Amedra Pharmaceuticals" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3e4d5027-7939-480f-ae19-82e764d9fa97&amp;name=daraprim-02.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DARAPRIMÂ 		
					</strong><br><span class="contentTableReg">pyrimethamine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52054-330</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PYRIMETHAMINE</strong> (PYRIMETHAMINE) </td>
<td class="formItem">PYRIMETHAMINE</td>
<td class="formItem">25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DARAPRIM;A3A</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52054-330-10</td>
<td class="formItem">100  in 1 BOTTLE, GLASS</td>
<td class="formItem">01/23/1953</td>
<td class="formItem">10/31/2016</td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:52054-330-95</td>
<td class="formItem">100  in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA008578</td>
<td class="formItem">01/23/1953</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Amedra Pharmaceuticals LLC
							(961668824)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3eb574dd-5a57-4b26-a2ba-46202d3931d3</div>
<div>Set id: 3e4d5027-7939-480f-ae19-82e764d9fa97</div>
<div>Version: 5</div>
<div>Effective Time: 20141031</div>
</div>
</div>Â <div class="DistributorName">Amedra Pharmaceuticals LLC</div></p>
</body></html>
